Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380688 | 0.89 | ESRRA (0.66) | ESRRAALDH1A1TSHRTTRKDM4E | |
| SCHEMBL4638505 | 0.85 | HTT (0.51) | ESRRASCN8ASCN10A | |
| SCHEMBL6857313 | 0.83 | L3MBTL1 (0.57) | ESRRAALDH1A1TSHRTTRKDM4E | |
| SCHEMBL4638408 | 0.82 | CFTR (0.50) | ALDH1A1KDM4EMEN1MAPTHPGD | |
| SCHEMBL29617695 | 0.82 | CFTR (0.50) | ALDH1A1KDM4EMEN1MAPTHPGD | |
| SCHEMBL2699247 | 0.81 | ESRRA (0.64) | ESRRAALDH1A1TSHRTTRKDM4E | |
| SCHEMBL8166036 | 0.81 | ESRRA (0.84) | ESRRAHPGDCYP3A4 | |
| SCHEMBL2381640 | 0.81 | ESRRA (0.84) | ESRRAHPGDCYP3A4 | |
| SCHEMBL2381635 | 0.81 | ESRRA (0.84) | ESRRAHPGDCYP3A4 | |
| SCHEMBL2382784 | 0.80 | ESRRA (0.64) | ESRRAALDH1A1TSHRTTRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | JANSSEN PHARAMCEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-7846953-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-07 | — | — | US | disclosed |
| EP-2129668-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2009-12-09 | — | — | EP | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | ESR2, ESRRA, ESRRB | ESRRA 2/4885ALDH1A1 2147/4885TSHR 257/4885 |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ALDH1A1 2124/4885TSHR 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.